# US 2019/0170766 A1 · Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0170766 A1
- Document ID: US20190170766A1
- Status: Published application
- Kind: A1
- Application number: 16/128,416
- Filed: 2018-09-11
- Published: 2019-06-06
- Earliest claimed: 2013-09-06
- Assignees: Aduro Biotech Holdings, Europe B.V.
- Applicants: Aduro Biotech Holdings, Europe B.V.
- Inventors: Hans Van Eenennaam; Andrea Van Elsas; Lilian Driessen; Jan Paul Medema
- Web page: https://patentgrep.com/patent/US20190170766A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2333/525: Tumor necrosis factor [TNF]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method of selecting an APRIL-binding antibody that detects APRIL in a human sample, comprising:
providing a library of candidate APRIL-binding antibodies;
contacting the candidate APRIL-binding antibodies with an APRIL polypeptide immobilized on a solid support, wherein said APRIL polypeptide comprises an APRIL receptor-binding region of APRIL, and wherein the APRIL polypeptide is bound to an APRIL-binding region of an APRIL receptor;
selecting an APRIL-binding antibody that binds to the APRIL polypeptide.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the contacting step is performed in the presence of human serum.

### Claim 17 (depends on 15)

A method according to claim 15, wherein the library comprises lymphocytes collected from a non-human mammal immunized with an agent selected to elicit an APRIL-specific immune response in the non-human mammal.

### Claim 18 (depends on 15)

A method according to claim 15, wherein the selected antibody binds to APRIL in complex with BCMA or TACI and to uncomplexed APRIL.

### Claim 19 (depends on 1)

A method for performing an ex vivo diagnostic test for the presence of APRIL in a human sample, comprising:
contacting a human sample with an APRIL-binding antibody selected according to the method of claim 1; and
detecting binding between APRIL polypeptides present in the human sample and the APRIL-binding antibody.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the APRIL-binding antibody is bound to a solid phase.

### Claim 21 (depends on 19)

A method according to claim 19, wherein the contacting step is performed in the presence of human serum.

### Claim 22 (depends on 19)

A method according to claim 19, wherein the APRIL-binding antibody binds to APRIL in complex with BCMA or TACI and to uncomplexed APRIL.

### Claim 23

A method for performing an ex vivo diagnostic test for the presence of APRIL in a human sample, comprising:
contacting a human sample with an APRIL-binding antibody which binds to APRIL in complex with BCMA or TACI and to uncomplexed APRIL; and
detecting binding between APRIL polypeptides present in the human sample and the APRIL-binding antibody.

### Claim 24 (depends on 23)

A method according to claim 23, wherein the APRIL-binding antibody is bound to a solid phase.

### Claim 25 (depends on 23)

A method according to claim 23, wherein the contacting step is performed in the presence of human serum.
